# Development of novel Amadorins for Diabetic Peripheral Neuropathy

> **NIH NIH R42** · PRAETEGO, INC. · 2021 · $458,155

## Abstract

PROJECT SUMMARY
Alzheimer’s disease (AD) is characterized by progressive cognitive dysfunction and widespread neuronal
loss, accumulation of amyloid b plaques and aggregation of hyperphosphorylated tau into neurofribrillary
tangles. There has been extensive interest in the use of antioxidants to treat AD and other
neurodegenerative pathologies. Normal brains are replete with glucose and ascorbate, both of which are
sources of advanced glycation end-products (AGE) via autooxidation in the presence of redox metal-ion
catalysts. AGE levels and carboxymethyl lysine, a predominant AGE modification, are increased in the
brain of AD patients. AGEs modify and crosslink proteins and AGEs were identified in both plaques and
tangles of AD brains. Indeed, glycation has the potential to be a driving influence in formation of both
plaques and tangles. Furthermore, AGEs induce toxic effects with formation of reactive oxygen species
through interaction with AGE receptors (RAGE), which are increased in AD brains. Preventing AGE
formation therefore represents a rational approach for the treatment of AD.
There is increasing recognition that there are similarities between the progression of neurodegeneration in
AD and diabetes with AGE formation being one suspected common causative factor. In our current Phase
II grant, we are comprehensively testing the in vivo efficacy of our lead compound, a proprietary atypical
antioxidant that inhibits redox metal-ion catalysis of oxidation, against diabetic peripheral neuropathy
using rodent models of type 1 and type 2 diabetes. In this supplement, we will use two different animal
models of AD to explore the therapeutic potential of our lead compound. This application offers a
propitious and synergistic opportunity to extend the investigation of our most potent lead compound to
non-diabetic AD models.

## Key facts

- **NIH application ID:** 10284641
- **Project number:** 3R42DK120063-02S1
- **Recipient organization:** PRAETEGO, INC.
- **Principal Investigator:** RAJA G KHALIFAH
- **Activity code:** R42 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $458,155
- **Award type:** 3
- **Project period:** 2018-09-19 → 2023-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10284641

## Citation

> US National Institutes of Health, RePORTER application 10284641, Development of novel Amadorins for Diabetic Peripheral Neuropathy (3R42DK120063-02S1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10284641. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*